Long-Term FVIII Expression with Reduced Bleeding Following Gene Transfer for Hemophilia A: Follow-up on the Dirloctocogene Samoparvovec Phase I/II Trial
Bibliographic record
Abstract
Introduction Hemophilia A (HA) is managed with factor (F)VIII replacement, or non-factor replacement therapy such as emicizumab. More recently, gene therapies have been under investigation for HA. These use a modified viral vector to deliver a functional FVIII gene to liver cells, aiming to safely provide long-term, stable FVIII expression to prevent bleeding. Dirloctocogene samoparvovec (SPK-8011), an investigational gene therapy, uses a modified adeno-associated viral vector designed to achieve clinically meaningful and sustained FVIII expression at the lowest possible dose. The ongoing Phase I/II trial (NCT03003533/NCT03432520) is evaluating the safety and efficacy of dirloctocogene samoparvovec, assessed by FVIII activity levels and patient-reported bleeding events. Method This open-label, multicenter, non-randomized trial enrolled participants into four dose cohorts, receiving a single intravenous dose ([ Fig. 1 ]). Fig. 1 Study design: a Phase I/II, open-label, multicenter, non-randomized trial Results At data cut-off (Oct 4, 2022), 24 participants were included across dosing cohorts. Median observation time was 191 (range: 2–285) weeks. Thirteen participants (54.2%) experienced 28 adverse events (AEs) related to dirloctocogene samoparvovec, including one serious AE, a Grade 2 alanine transaminase (ALT, a liver enzyme) elevation resulting in elective hospitalization for intravenous corticosteroid administration. Eight participants (33.3%) experienced 26 immunomodulatory therapy-related AEs. No FVIII inhibitors or thrombotic events were reported. Fourteen participants had transient ALT elevations per CTCAE Grade 1–3, with these being Grade 1 in 12/14 participants. Among 18 participants with≥1 year of follow-up, 16 showed sustained FVIII activity, with most in the mild HA range, and two lost FVIII expression within the first year following a presumed capsid immune response. These two participants were not included in efficacy analyses. In participants previously using prophylaxis (n=17) who received dirloctocogene samoparvovec, mean all-bleeds annualized bleeding rate (ABR) was reduced by 82% (95% confidence interval [CI]: 55–93%): ABR of 6.88 (95% CI: 4.17–11.37) pre-vector infusion versus 1.21 (0.55–2.66) post infusion. In participants previously using on-demand treatment (n=5), there was a 99% reduction (95% CI: 98–100%) in all-bleeds ABR: 27.17 (95% CI: 18.46–39.98) pre-vector infusion versus 0.23 (0.13–0.42) post infusion. Median annualized FVIII infusion rates (AIRs) starting 28 days post-vector infusion were 0.3 (interquartile range: 0.0–1.4) versus 85.5 (40.0–104.0) pre infusion. Conclusion With up to 5 years of follow-up (range: 2–285 weeks), a dirloctocogene samoparvovec infusion in participants with HA resulted in sustained year-to-year FVIII expression and clinically meaningful ABR and AIR reductions. No major safety signals were reported, indicating dirloctocogene samoparvovec was well tolerated. Publication History Article published online: 26 February 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".